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AIM: To assess whether a liver specific nitric oxide (NO) donor (V-PYRRO/NO)
would prevent the development of portal hypertension and liver fibrosis in rats with
bile duct ligation (BDL).
METHODS: Treatment (placebo or V-PYRRO/NO 0.53 micromol/kg per hour) was
administered i.v. to rats 2 d before BDL (D-2) and maintained until the day of
hemodynamic measurement (D26). Intra-hepatic NO level was estimated by
measuring liver cGMP level. Effects of V-PYRRO/NO on liver fibrosis and lipid
peroxidation were also assessed.
RESULTS: Compared to placebo treatment, V-PYRRO/NO improved splanchnic
hemodynamics in BDL rats: portal pressure was significantly reduced by 27%
(P<0.0001) and collateral circulation development was almost completely blocked
(splenorenal shunt blood flow by 74%, P=0.007). Moreover, V-PYRRO/NO
significantly prevented liver fibrosis development in BDL rats (by 30% in hepatic
hydroxyproline content and 31% in the area of fibrosis, P<0.0001 respectively), this
effect being probably due to a decrease in lipid peroxidation by 44% in the hepatic
malondialdehyde level (P=0.007). Interestingly, we observed a significant and
expected increase in liver cGMP, without any systemic hemodynamic effects (mean
arterial pressure, vascular systemic resistance and cardiac output) in both sham-
operated and BDL rats treated with V-PYRRO/NO. This result is in accordance with
studies on V-PYRRO/NO metabolism showing a specific release of NO in the liver.
CONCLUSION: Continuous administrations of V-PYRRO/NO in BDL rats improved
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